at10 presentation
TRANSCRIPT
![Page 1: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/1.jpg)
Antithrombotic Therapy for VTE Disease: 10th editionALLYSON CORD, PHARMD CANDIDATE 2016
![Page 2: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/2.jpg)
VENOUS THROMBOEMBOLISM
DVT: blood clot formed in a vein that partially or completely blocks circulation
PE: obstruction of the pulmonary artery or one of its branches by material that originated elsewhere in the body (thrombus)
Causes: Virchow’s triad Alterations in blood flow (stasis) Vascular endothelial injury Hypercoagulable state
Malignancy, Factor V Leiden mutation, protein S deficiency, protein C deficiency, antiphospholipid antibodies, IBD, pregnancy
![Page 3: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/3.jpg)
Clinical Presentation DVT
Unilateral extremity swelling, discoloration, pain, tenderness
PE SOB Chest pain Tachypnea Tachycardia Hypotension (hemodynamically unstable or massive PE)
SBP <90 mmHg for a period >15 minutes, or requires vasopressors or inotropic support
http://www.dvtforum.com/index.asp?action=start
![Page 4: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/4.jpg)
Diagnosis D-dimer
Degradation product of fibrin clot Sensitive but not specific
Radiographic contrast studies – venography, pulmonary angiography Gold standard
Most accurate and reliable Expensive and invasive
Ultrasound Less invasive
![Page 5: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/5.jpg)
Etiology Classification
Provoked Transient/reversible
Surgery, pregnancy, immobilization Persistent
Malignancy, indefinite hypercoagulable state Unprovoked
Unidentifiable cause
![Page 6: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/6.jpg)
Anticoagulation Therapy for VTE DiseaseCHEST GUIDELINE, 10TH ED
![Page 7: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/7.jpg)
Choice of Anticoagulant DVT/PE and no cancer (Grade 2B)
Recommend dabigatran, rivaroxaban, apixaban, or edoxaban over VKA therapy, and VKA therapy over LMWH
DVT/PE and cancer (Grade 2C) Recommend LMWH over dabigatran, rivaroxaban, apixaban, edoxaban, or
VKA therapy
No need to change the choice of anticoagulant after the first 3 months of therapy (Grade 2C)
NOAC > VKA > LMWH
Cancer = LMWH
![Page 8: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/8.jpg)
NOAC evidence 4 new RCTs and extensive clinical experience
Risk reduction similar between NOACs and VKA Risk reduction greater with LMWH than VKA in patients with cancer Risk reduction seems to be similar between all NOACs
No direct comparison Risk of bleeding less with NOACs than VKA
GI bleeding may be higher, though Risk may be less with apixaban
Risk of fatal bleeding similar between VKA and NOACs Conclusion, less bleeding and greater convenience with NOACs
![Page 9: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/9.jpg)
Parenteral Anticoagulation Dosing
UFH 80 U/kg IV bolus followed by 18
U/kg/hr 5000U IV bolus followed by 1000 U/hr
Enoxaparin 1 mg/kg SQ Q12H 1.5 mg/kg SQ QD CrCl < 30: 1 mg/kg SQ Q24H
Fondaparinux < 50kg: 5mg SQ QD 50-100kg: 7.5mg SQ QD > 100kg: 10mg SQ QD
Tinzaparin 175 U/kg SQ QD CrCl < 30: use with caution
Nadroparin 171 U/kg SQ QD CrCl 30-50: reduce dose by 25-
33% CrCl < 30: CI
Dalteparin – off-label
![Page 10: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/10.jpg)
Oral Anticoagulation Therapy Vitamin K Antagonist - warfarin
Started on day 1 or 2 of parenteral anticoagulation Maintain overlap for at least 5 days and INR therapeutic for 48 hours
INR goal = 2-3 Many diet, drug, and disease interactions
OR NOAC – rivaroxaban, apixaban, edoxaban, dabigatran
Preferred VTE treatment
![Page 11: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/11.jpg)
Rivaroxaban (Xarelto)Dosing DVT/PE treatment: 15mg BID x 21 days followed by 20mg
QD Take with food Extremes in weight do not influence Does not require parenteral anticoagulation prior to initiation
Reduction in risk of recurrence: 20mg QD Renal and hepatic impairment
CrCl < 30: avoid use Moderate-severe hepatic impairment: avoid use
![Page 12: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/12.jpg)
Rivaroxaban (Xarelto)Characteristics ADR
Bleeding/thrombosis Spinal/epidural hematoma
DDI CYP 3A4 (major) CYP 2J2 (minor) P-gp
Pregnancy C D/c 24 hours prior to surgery
CrCl < 50: consider d/c 3-5 days prior
![Page 13: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/13.jpg)
Apixaban (Eliquis)Dosing DVT treatment: 10mg BID x 7 days followed by 5mg BID
Does not require parenteral anticoagulation prior to initiation Reduction in risk of recurrence: 2.5mg BID after at least 6 months of
DVT treatment Renal impairment
CrCl < 30: use with caution Under nonvalvular atrial fibrillation
≥ 80 yoa AND weighs ≤ 60kg or SCR ≥ 1.5 reduce dose by 50% Hepatic impairment
Moderate: use with caution Severe: not recommended
![Page 14: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/14.jpg)
Apixaban (Eliquis)Characteristics ADR
Bleeding/thrombosis Spinal/epidural hematoma
DDI CYP 3A4 (major)
Reduce dose by 50% CYP 1A2, 2C19, 2C8, 2C9 (minor) P-gp
Pregnancy B D/c 24-48 hours prior to surgery
![Page 15: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/15.jpg)
Edoxaban (Savaysa)Dosing DVT/PE treatment: 60mg QD
Requires 5-10 days of parenteral anticoagulation prior to initiation Weight dose adjustment
≤ 60kg: reduce dose by 50% Renal impairment
CrCl > 95: avoid CrCl 15-50: reduce dose by 50% CrCl < 15: avoid
Hepatic impairment Moderate-severe: avoid
![Page 16: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/16.jpg)
Edoxaban (Savaysa)Characteristics ADR
Bleeding/thrombosis Spinal/epidural hematoma Abnormal LFTs
DDI with specific P-gp inhibitors Verapamil, quinidine, macrolides, oral itraconazole, oral ketoconazole Reduce dose by 50%
Pregnancy C D/c 24 hours prior to surgery
![Page 17: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/17.jpg)
Edoxaban (Savaysa)
CrCl > 95 CrCl 95-51 CrCl 50-15 CrCl < 15
> 61kg Avoid 60mg 30mg Avoid
P-gp Avoid 30mg 15mg Avoid
≤ 61kg Avoid 30mg 15mg Avoid
P-gp Avoid 15mg avoid Avoid
![Page 18: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/18.jpg)
Dabigatran (Pradaxa)Dosing DVT/PE treatment/prevention: 150mg BID
After 5-10 days of parenteral anticoagulation Take with full glass of water Dispense in original container
Discard 4 months after opening Renal
CrCl < 50 and concomitant P-gp: 75mg BID CrCl ≤ 30: dose not provided
Non-valvular a fib with CrCl 15-30: 75mg BID If with P-gp, avoid
CrCl < 15: not studied, CI per CHEST Hepatic
Severe impairment: avoid
![Page 19: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/19.jpg)
Dabigatran (Pradaxa)
Characteristics ADR
Bleeding/thrombosis Spinal/epidural hematoma GI upset
DDI P-gp inhibitor
Pregnancy C d/c 1-2 days or 3-5 days (CrCl <
50) before surgery
Reversal Idarucizumab (Praxbind)
5g dose (2 2.5g vials) Give within 15 mins
Dialyzable
![Page 20: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/20.jpg)
NOAC ComparisonNOAC Parenteral
neededWeight adj DDI Reversal Unique
Rivaroxaban No No 3A4, P-gp No Take with food
Apixaban No ~ No 3A4, P-gp No Pregnancy B
Edoxaban Yes Yes P-gp No CrCl > 95: avoid
Dabigatran Yes No P-gp Praxbind, dialyzable
GI upset
![Page 21: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/21.jpg)
Thrombophilia Recommended treatment: UFH or LMWH followed by VKA
Sufficient data not available regarding safety and efficacy of NOACs in patients with thrombophilia
RAPS: rivaroxaban vs enoxaparin with warfarin in APS
Antithrombin deficiency Heparin resistance – need larger doses
Not as much AT for heparin to reduce Protein C deficiency
Warfarin-induced skin necrosis
![Page 22: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/22.jpg)
Duration of Anticoagulant Therapy Active treatment = 3-6 months
Secondary prophylaxis Primary risk factor – provoked vs unprovoked
Provoked by transient/reversible risk factor = lowest risk of recurrence 3 months
Unprovoked/unidentifiable = moderately high risk of recurrence Base duration of therapy on secondary risk factors and bleeding risk
Provoked by progressive/persistent factor = highest risk of recurrence Indefinite therapy
Secondary risk factors – location and history Second episode = indefinite therapy UE or isolated distal (unprovoked or transient provoked) = 3 months
Indefinite therapy only recommend in low-moderate bleeding risk!
![Page 23: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/23.jpg)
Management of Recurrent VTE on Anticoagulant Therapy
Unusual occurrence so reevaluate: Diagnosis Compliance Underlying malignancy
If occurs while on therapeutic VKA or NOAC therapy, suggest switching to LMWH therapy at least temporarily At least 1 month
If occurs while on long-term LMWH, suggest increasing dose by 1/4 -1/3
![Page 24: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/24.jpg)
Aspirin for Extended Treatment of VTE
“In patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy and do not have a contraindication to aspirin, we suggest aspirin over no aspirin to prevent recurrent VTE (Grade 2B).” Not a reasonable alternative
80% reduction vs 30% Additional indications
![Page 25: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/25.jpg)
Systemic Thrombolytic Therapy for PE
Suggested indications for thrombolytic use PE associated with hypotension Acute PE that deteriorates after starting anticoagulant therapy
Suggest using a peripheral vein over catheter-directed thrombolysis
Only use if low risk of bleeding!
If massive PE with high bleeding risk, failed systemic thrombolysis, or shock, suggest catheter-assisted thrombus removal Only if appropriate expertise and resources available
![Page 26: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/26.jpg)
Compression Stockings to Prevent PTS
“In patients with acute DVT of the leg, we suggest not using compression stockings routinely to prevent PTS (Grade 2B)” Post-thrombotic syndrome: chronic complication of DVT resulting in
chronic venous insufficiency Larger RCT showed no benefit A trial of compression stockings may be tried for s/s associated with
PTS
![Page 27: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/27.jpg)
Whether to Anticoagulate Subsegmental PE
Subsegmental PE: no involvement of the more proximal pulmonary arteries Low risk of recurrent VTE clinical surveillance
As long as no DVT also present More likely a false positive or arose from a small DVT
High risk of recurrent VTE anticoagulation Evaluate bleeding risk
![Page 28: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/28.jpg)
Treatment of Acute PE Out of the Hospital
“In patients with low-risk PE and whose home circumstances are adequate, we suggest treatment at home or early discharge over standard discharge (Grade 2B).” Standard discharge: after first 5 days of treatment
![Page 29: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/29.jpg)
Summary
Non-Cancer: NOAC > VKA > LMWH Cancer: LMWH Recurrent: Switch to LMWH or increase LMWH dose ASA: consider upon anticoagulant d/c Thrombolytic: only in massive or deteriorating PE Compression stockings: do not routinely use Subsegmental: base therapy on risk
![Page 30: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/30.jpg)
References DiPiro JT, Talbert RL, Yee GC, et. al. Pharmacotherapy: A Pathophysiologic
Approach, Ninth Edition. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE
disease: Antithrombotic Therapy and Prevention of Thrombosis, 10th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2016;149(2):315-352.
Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123(12):1794-1801.
Lexi-Drugs. Lexicomp Online. Wolters Kluwer Health, Inc. Hudson, OH. Available at: http://online.lexi.com. Accessed February 4, 2016.
Bauer KA. Management of inherited thrombophilia. UpToDate. Wolters Kluwer Health, Inc. Hudson, OH. Available at: http://www,uptodate.com/contents/management-of-inherited-thrombophilia
![Page 31: AT10 Presentation](https://reader036.vdocuments.mx/reader036/viewer/2022081520/5873031b1a28ab99088b4ba7/html5/thumbnails/31.jpg)
Questions?